Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Safety and Effectiveness of Luveltamab Tazevibulin (STRO-002) for Infants and Children Under 12 with Acute Myeloid Leukemia (AML)

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a specific type of blood cancer called Acute Myeloid Leukemia (AML) in infants and children under 12 years old. The trial is investigating a treatment using a drug called Luveltamab Tazevibulin (STRO-002), which is given as a solution through a vein, known as an infusion. This study aims to understand how safe and effective this drug is for young patients with this particular type of leukemia.

Participants in the study will receive the drug Luveltamab Tazevibulin to see how it affects their condition. The study will monitor the participants over time to observe the drug's effects on their leukemia, including how well it works and any side effects that may occur. The study will also measure how long the drug stays in the body and how the body responds to it.

The main goal of the study is to evaluate the effectiveness of Luveltamab Tazevibulin when used alone, without other treatments. Researchers will look at various outcomes, such as the rate of complete remission, which means the disappearance of all signs of cancer in response to treatment. They will also assess how long the remission lasts, the overall survival of the participants, and any adverse effects experienced during the trial. This information will help determine the potential benefits and risks of using this drug in young patients with AML.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be required to sign an informed consent form. If applicable, a pediatric assent form will also need to be signed.

    If you have reached puberty, you will receive reproductive education and discuss the potential effects of the study therapy on reproduction with your parent(s) or guardian(s).

  2. Step 2

    Initial health assessments

    A series of health assessments will be conducted to confirm your eligibility. This includes a diagnosis of relapsed or refractory acute myeloid leukemia (AML) with a specific genetic marker.

    A lumbar puncture will be performed to check for central nervous system involvement. Other tests will include blood tests to check liver and kidney function, heart function tests, and a pregnancy test if applicable.

  3. Step 3

    Treatment administration

    You will receive the study drug, luveltamab tazevibulin (STRO-002), as a solution for infusion. This means the medication will be given through a vein.

    The dosage, frequency, and duration of administration will be determined by the study protocol and your healthcare team.

  4. Step 4

    Monitoring and follow-up

    Throughout the study, regular monitoring will be conducted to assess your response to the treatment and to check for any side effects.

    This will include blood tests, imaging studies, and other necessary evaluations as determined by your healthcare team.

  5. Step 5

    End of treatment

    At the end of the treatment period, a final set of assessments will be conducted to evaluate the overall effectiveness of the therapy and your health status.

    You will be advised on any necessary follow-up care or additional treatments based on the study findings and your individual health needs.

Who can join the trial?

11 criteria

  • Must sign an informed consent form. If the participant is a child, a parent or guardian must also sign a form.
  • Females who have started menstruating and males who have reached puberty must agree to receive education about reproduction and discuss potential side effects of the study treatment on reproduction with their parents or guardians.
  • Females who have started menstruating must have a negative pregnancy test within 7 days before the first dose of the study drug. All participants who have reached puberty and are sexually active must agree to use condoms during heterosexual contact. Females may also use other birth control methods if advised by their doctor. Pregnancy prevention must continue during the study, during any breaks in treatment, and for at least 6 months after stopping the study drug.
  • Must have a diagnosis of relapsed or refractory Acute Myeloid Leukemia (AML) with a specific genetic change called CBFA2T3::GLIS2 fusion. The disease must have returned or not responded to treatment, with at least 5% of the bone marrow affected by leukemia. A lumbar puncture is required at screening to check for disease in the central nervous system (CNS). Participants with certain CNS conditions (CNS1 and CNS2) are eligible.
  • Must be younger than 12 years old.
  • Must have a Lansky performance score of 50 or higher, which measures the ability to perform daily activities.
  • Must have a direct bilirubin level less than 1.5 times the upper limit of normal. This is a liver function test. Participants with Gilbert's disease must also meet this requirement.
  • Must have ALT and AST levels less than 2.5 times the upper limit of normal, unless related to leukemia. These are liver enzymes. Participants with liver involvement may have levels up to 5 times the upper limit.
  • Must have a creatinine clearance or glomerular filtration rate of 70 or higher, or a serum creatinine level based on age and gender. These tests measure kidney function.
  • Must have a corrected QT interval (QTcF) of less than 450 milliseconds. This is a heart rhythm measurement.
  • Must have a left ventricular ejection fraction greater than 50% as measured by an echocardiogram (ECHO). This measures how well the heart pumps blood.

Who cannot join the trial?

9 criteria

  • Patients with any other active cancer besides Acute Myeloid Leukemia (AML) cannot participate.
  • Patients who have received another investigational drug within the last 30 days are excluded.
  • Patients with uncontrolled infections are not eligible.
  • Patients with severe heart problems, such as heart failure or recent heart attack, cannot join the study.
  • Patients with severe liver disease are excluded.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients with a history of allergic reactions to similar drugs are not eligible.
  • Patients with a history of drug or alcohol abuse within the last year are excluded.
  • Patients with any condition that the study doctors believe would make it unsafe for them to participate are not eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Luveltamab Tazevibulin (STRO-002) is a medication being studied for its potential to treat a specific type of leukemia in young children. This medication is designed to target and attack cancer cells in the body, helping to stop their growth and spread. The goal of using this medication in the trial is to see how effective it is in treating the leukemia and to understand its safety and how it behaves in the body. By focusing on this medication, researchers hope to find a new treatment option for children with this type of cancer.

What is already known about the treatment

Luveltamab Tazevibulin – This medication is administered as an injection and is currently being studied in clinical trials for its effectiveness and safety in treating a specific type of Acute Myeloid Leukemia (AML) in young children. It is not yet widely used in medicine, as it is still under investigation. The main purpose of this medication is to treat AML, a type of cancer that affects the blood and bone marrow. At the molecular level, Luveltamab Tazevibulin works by targeting and disrupting specific proteins involved in the growth and survival of cancer cells. It is classified as an investigational drug, meaning it is still being tested and is not yet approved for general use.

Investigated diseases

Acute Myeloid Leukemia (AML) – Acute Myeloid Leukemia is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. The disease progresses quickly and can lead to symptoms such as fatigue, fever, frequent infections, and easy bruising or bleeding. As the abnormal cells multiply, they can spread to other parts of the body, including the liver, spleen, and central nervous system. The progression of AML can vary, with some cases advancing more rapidly than others. The disease requires medical attention to manage its effects on the body.
Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase ITrial ID2023-506240-16-00Protocol codeREFRaME-P1Estimated enrolment31 patientsSponsorSutro Biopharma Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.